Gold Resource Corp (GORO)
The trading levels of GORO exploded on Tuesday after the company delivered strong operating results.
For the first quarter ended March 31, 2014, GORO reported net income of $7.1 million, or $0.13 per share, production of 23,734 ounces precious metal gold equivalent and decreased its total cash cost by 18% over the first quarter of 2013.
Gold Resource Corp (GORO) is a mining company focused on production and pursuing development of gold and silver projects that feature low operating costs and produce high returns on capital.
**
evdy.jpg Everyday Health, Inc. (EVDY)
Shares of EVDY are soaring on Tuesday's trading session, after the company reported its financial results above consensus.
For the first quarter 2014, EVDY posted revenue of $37.5 million, a 23% increase year over year, while its non-GAAP net loss improved to ($2.5) million from ($6.8) million in the first quarter of 2013.
EVDY expects second quarter 2014 total revenue to be in the range of $40.5 million ? $41.0 million.
Everyday Health, Inc. (EVDY) is a leading provider of digital health and wellness solutions.
**
Halozyme Therapeutics, Inc. (HALO)
Tuesday's market activity worked out for the price of HALO stock, which jumped after an independent data monitoring panel supported the continued enrollment of patients for a phase 2 trial of the company's PEGPH20, an experimental pancreatic cancer treatment.
HALO in April halted enrollment and dosing in the phase 2 trial (Study 202 ) of PEGPH20, which is an advanced version of its intravenous drug delivery system for chemotherapy
HALO also reported positive top-line data from studies with HTI-501 in cellulite and Hylenex with insulin pumps.
For the first quarter 2014, HALO posted revenues of $12.0 million and a net loss of $26.5 million, or $0.22 per share, compared to revenues of $11.8 million and a net loss of $19.3 million, or $0.17 per share, for the first quarter of 2013.
Halozyme Therapeutics, Inc. (HALO) is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care.
**
Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer